Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen | Zendy

Nils von Hentig | Zendy; Pavel Kaykhin | Zendy; Christoph Stephan | Zendy; Errol Babacan | Zendy; Martin Stürmer | Zendy; Schlomo Staszewski | Zendy; Jörn Lötsch | Zendy

Open Access

Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen

Author(s) -

Nils von Hentig,

Pavel Kaykhin,

Christoph Stephan,

Errol Babacan,

Martin Stürmer,

Schlomo Staszewski,

Jörn Lötsch

Publication year - 2008

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01565-07

Subject(s) - atazanavir , lopinavir , protease inhibitor (pharmacology) , virology , ritonavir , salvage therapy , regimen , human immunodeficiency virus (hiv) , lentivirus , medicine , pharmacology , chemistry , viral load , viral disease , antiretroviral therapy , chemotherapy

The human immunodeficiency virus protease inhibitor combination of atazanavir (ATV)-lopinavir-ritonavir was reported to exhibit a mutual pharmacoenhancement of plasma lopinavir and ATV concentrations which may be beneficial for salvage patients. We identified 17 patients in our pharmacokinetic database taking this combination and found conflicting results. Plasma concentrations of both ATV and lopinavir were modestly, although not significantly, decreased when the drugs were coadministered. Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research